Literature DB >> 11986130

PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium.

Lakshmi N Yatham1, Peter F Liddle, I-Shin Shiah, Raymond W Lam, Elton Ngan, Gayle Scarrow, Miguel Imperial, Jon Stoessl, Vesna Sossi, Thomas J Ruth.   

Abstract

OBJECTIVE: Although dopaminergic hyperactivity has been implicated in mania, the precise location in the brain of the abnormality is unclear. This study assessed presynaptic dopamine function in neuroleptic- and mood-stabilizer-naive nonpsychotic first-episode manic patients before and after treatment with divalproex sodium by measuring [(18)F]6-fluoro-L-dopa ([(18)F]DOPA) uptake in the striatum with positron emission tomography (PET).
METHOD: Thirteen patients with DSM-IV bipolar I disorder, manic episode, and 13 healthy comparison subjects underwent [(18)F]DOPA PET scans. Ten of the 13 patients had repeat PET scans 2-6 weeks after beginning treatment with divalproex sodium monotherapy. [(18)F]DOPA uptake rate constants (K(i) values) in the striatum were calculated by using graphical analysis with activity from the occipital cortex as the input function.
RESULTS: No significant differences in [(18)F]DOPA uptake rate constants in the striatum were found between the manic patients and the comparison subjects. After treatment with divalproex sodium, [(18)F]DOPA rate constants were significantly reduced in the patients and were lower in the patients than in the comparison subjects.
CONCLUSIONS: Although presynaptic dopamine function as reflected by [(18)F]DOPA uptake is not altered in mania, presynaptic dopamine function in manic patients was lower after treatment with divalproex sodium.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986130     DOI: 10.1176/appi.ajp.159.5.768

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  19 in total

1.  Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

2.  The underlying neurobiology of bipolar disorder.

Authors:  Husseini K Manji; Jorge A Quiroz; Jennifer L Payne; Jaskaran Singh; Barbara P Lopes; Jenilee S Viegas; Carlos A Zarate
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

Review 3.  Molecular imaging in patients with mood disorders: a review of PET findings.

Authors:  Qiaozhen Chen; Weibo Liu; Huichun Li; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 4.  Lurasidone: a new treatment option for bipolar depression-a review.

Authors:  Radhika Bawa; Jonathan R Scarff
Journal:  Innov Clin Neurosci       Date:  2015 Jan-Feb

5.  Normalization of risperidone-induced hyperprolactinemia with the addition of aripiprazole.

Authors:  Larry E Shores
Journal:  Psychiatry (Edgmont)       Date:  2005-03

6.  Incentive-elicited mesolimbic activation and externalizing symptomatology in adolescents.

Authors:  James M Bjork; Gang Chen; Ashley R Smith; Daniel W Hommer
Journal:  J Child Psychol Psychiatry       Date:  2009-12-11       Impact factor: 8.982

Review 7.  Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide.

Authors:  Abdulla Badawy
Journal:  Psychopharmacology (Berl)       Date:  2013-07-05       Impact factor: 4.530

8.  Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania.

Authors:  Benicio N Frey; Samira S Valvassori; Gislaine Z Réus; Márcio R Martins; Fabrícia C Petronilho; Katrine Bardini; Felipe Dal-Pizzol; Flávio Kapczinski; João Quevedo
Journal:  J Psychiatry Neurosci       Date:  2006-09       Impact factor: 6.186

Review 9.  The dopamine hypothesis of schizophrenia: version III--the final common pathway.

Authors:  Oliver D Howes; Shitij Kapur
Journal:  Schizophr Bull       Date:  2009-03-26       Impact factor: 9.306

10.  Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease.

Authors:  Suzanne Reeves; Richard Brown; Robert Howard; Paul Grasby
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.